Sales in the 340B outpatient drug discount program rose 23.4% to $66bn in 2023, according to the Health Resources and Services Administration, continuing a string of mostly 20%-plus increases in the program’s sales since 2015.
Key Takeaways
- Sales in the 340B outpatient drug discount program rose more than 23% to $66bn in 2023, continuing a long string of significant annual increases in...
HRSA’s report could provide fodder for legislative efforts to improve oversight and transparency in the 340B program, but the upcoming US elections likely will dictate...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?